Lisa R Tannock Selected Research

Biglycan

1/2018	Elevated circulating TGF-β is not the cause of increased atherosclerosis development in biglycan deficient mice.
12/2017	Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition.
1/2016	Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atherosclerosis.
2/2015	A brief elevation of serum amyloid A is sufficient to increase atherosclerosis.
10/2014	Biglycan deficiency: increased aortic aneurysm formation and lack of atheroprotection.
7/2014	Increased atherosclerosis in mice with increased vascular biglycan content.
8/2013	Prevention of TGFβ induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr-/- mice.
9/2011	Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy.
3/2008	Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development.
1/2002	Triglyceride-rich lipoproteins from subjects with type 2 diabetes do not demonstrate increased binding to biglycan, a vascular proteoglycan.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lisa R Tannock Research Topics

Disease

27	Atherosclerosis 01/2020 - 01/2002
7	Obesity 01/2022 - 01/2010
6	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 03/2008
6	Dyslipidemias (Dyslipidemia) 12/2020 - 09/2004
6	Hyperlipidemias (Hyperlipidemia) 12/2017 - 11/2006
5	Inflammation (Inflammations) 01/2022 - 08/2007
5	Diabetes Mellitus 12/2020 - 07/2008
4	Type 2 Diabetes Mellitus (MODY) 05/2013 - 01/2002
4	Insulin Resistance 04/2011 - 06/2005
3	Abdominal Aortic Aneurysm 01/2022 - 10/2014
3	Weight Gain 03/2019 - 06/2010
3	Diabetic Nephropathies (Diabetic Nephropathy) 12/2017 - 06/2010
3	Hypertrophy 12/2017 - 06/2010
3	Hypoglycemia (Reactive Hypoglycemia) 03/2012 - 06/2010
2	Acute-Phase Reaction 01/2018 - 02/2009
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 01/2010
2	Vascular Diseases (Vascular Disease) 10/2014 - 12/2010
2	Weight Loss (Weight Reduction) 05/2013 - 01/2010
2	Body Weight (Weight, Body) 03/2012 - 04/2011
1	Pancreatitis 12/2020
1	Endocrine System Diseases (Endocrine Diseases) 12/2020
1	Hypogonadism (Hypergonadotropic Hypogonadism) 03/2019
1	Relative Energy Deficiency in Sport 03/2019
1	Overtraining Syndrome 03/2019
1	Hypertension (High Blood Pressure) 01/2019
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2019
1	Cataract (Cataracts) 01/2019
1	Cognitive Dysfunction 01/2019
1	Stroke (Strokes) 01/2019
1	Hemorrhagic Stroke 01/2019
1	Ischemic Stroke 01/2019
1	Erectile Dysfunction 01/2019
1	Tendinopathy (Tendonitis) 01/2019
1	Gender Dysphoria 01/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2019
1	Thrombosis (Thrombus) 01/2019
1	Myocardial Infarction 01/2019
1	Neoplasms (Cancer) 01/2019
1	Rhabdomyolysis 01/2019
1	Albuminuria 12/2017
1	Acute Coronary Syndrome 01/2016
1	Atherosclerotic Plaque (Atheroma) 01/2016
1	Aortic Rupture 10/2014
1	Aneurysm (Aneurysms) 10/2014
1	Aortic Aneurysm (Aneurysm, Aortic) 10/2014
1	Hypercholesterolemia 10/2012

Drug/Important Bio-Agent (IBA)

13	Proteoglycans (Proteoglycan)IBA 01/2018 - 01/2002
11	LipidsIBA 12/2020 - 08/2007
11	Lipoproteins (Lipoprotein)IBA 12/2020 - 01/2002
10	BiglycanIBA 01/2018 - 01/2002
9	Serum Amyloid A Protein (Serum Amyloid A)IBA 01/2022 - 01/2010
7	ApolipoproteinsIBA 01/2016 - 01/2002
7	Insulin (Novolin)FDA Link 03/2012 - 09/2004
6	CholesterolIBA 01/2022 - 09/2004
6	Angiotensin IIIBA 01/2022 - 03/2008
6	oxidized low density lipoproteinIBA 01/2017 - 11/2003
5	Apolipoproteins E (ApoE)IBA 01/2022 - 01/2002
5	Apolipoproteins B (ApoB)IBA 01/2018 - 01/2002
5	LDL Receptors (LDL Receptor)IBA 07/2014 - 09/2004
4	Triglycerides (Triacylglycerol)IBA 12/2020 - 01/2002
4	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018 - 06/2010
2	Testosterone (Sustanon)FDA Link 03/2019 - 10/2012
2	Hormones (Hormone)IBA 01/2019 - 10/2012
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 12/2008
2	Estrogens (Estrogen)FDA Link 01/2019 - 10/2012
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 11/2003
2	CollagenIBA 10/2014 - 08/2013
2	AlbuminsIBA 09/2011 - 06/2010
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 08/2011 - 01/2010
2	low density lipoprotein inhibitorIBA 06/2010 - 11/2003
2	C-Reactive ProteinIBA 12/2008 - 08/2007
2	HexosaminesIBA 11/2006 - 01/2002
1	Sucrose (Saccharose)IBA 01/2022
1	InflammasomesIBA 01/2019
1	Vasodilator Agents (Vasodilators)IBA 01/2019
1	Vasoconstrictor AgentsIBA 01/2019
1	angiotensin I (1-7)IBA 01/2019
1	Angiotensin-Converting Enzyme 2IBA 01/2019
1	Neutralizing AntibodiesIBA 01/2018
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2018
1	Protein Isoforms (Isoforms)IBA 01/2018
1	Heparin Cofactor IIIBA 01/2016
1	Proteinase-Activated ReceptorsIBA 01/2016
1	Thrombin FDA Link 01/2016
1	Small Leucine-Rich ProteoglycansIBA 01/2016
1	ElastinIBA 10/2014
1	Actins (F Actin)IBA 07/2014
1	VLDL LipoproteinsIBA 05/2013
1	HDL LipoproteinsIBA 05/2013
1	salicylhydroxamic acid (SHAM)IBA 10/2012
1	AndrogensIBA 10/2012
1	Gonadal Steroid Hormones (Sex Hormones)IBA 10/2012

Therapy/Procedure

5	Glycemic Control 03/2012 - 08/2007
4	Therapeutics 01/2019 - 08/2007
2	Transplantation 07/2008 - 04/2008
2	Organ Transplantation 07/2008 - 04/2008
1	Injections 02/2015
1	Ovariectomy (Oophorectomy) 10/2012
1	Orchiectomy (Orchidectomy) 10/2012
1	Fat-Restricted Diet (Diet, Fat Restricted) 10/2012